Tags

Type your tag names separated by a space and hit enter

Cannabidiol was ineffective for manic episode of bipolar affective disorder.
J Psychopharmacol. 2010 Jan; 24(1):135-7.JP

Abstract

The pharmacological profile of cannabidiol (CBD) has several characteristics in common with drugs known to benefit bipolar affective disorder (BAD), leading to the hypothesis that CBD may have therapeutic properties in BAD. Therefore, the aim of the present report was to directly investigate for the first time the efficacy and safety of CBD in two patients with BAD. Both patients met DSM IV criteria for bipolar I disorder experiencing a manic episode without comorbid conditions. This was an inpatient study, and the efficacy, tolerability and side effects were assessed. Both patients received placebo for the initial 5 days and CBD from the 6th to 30th day (initial oral dose of 600 mg reaching 1200 mg/ day). From the 6th to the 20th day, the first patient (a 34-year-old woman) received adjunctive olanzapine (oral dose of 10-15 mg). On day 31, CBD treatment was discontinued and replaced by placebo for 5 days. The first patient showed symptoms improvement while on olanzapine plus CBD, but showed no additional improvement during CBD monotherapy. The second patient (a 36-year-old woman) had no symptoms improvement with any dose of CBD during the trial. Both patients tolerated CBD very well and no side-effects were reported. These preliminary data suggest that CBD may not be effective for the manic episode of BAD.

Authors+Show Affiliations

Department of Neuropsychiatry and Medical Psychology, Faculty of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. awzuardi@fmrp.usp.brNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18801823

Citation

Zuardi, Aw, et al. "Cannabidiol Was Ineffective for Manic Episode of Bipolar Affective Disorder." Journal of Psychopharmacology (Oxford, England), vol. 24, no. 1, 2010, pp. 135-7.
Zuardi A, Crippa J, Dursun S, et al. Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol. 2010;24(1):135-7.
Zuardi, A., Crippa, J., Dursun, S., Morais, S., Vilela, J., Sanches, R., & Hallak, J. (2010). Cannabidiol was ineffective for manic episode of bipolar affective disorder. Journal of Psychopharmacology (Oxford, England), 24(1), 135-7. https://doi.org/10.1177/0269881108096521
Zuardi A, et al. Cannabidiol Was Ineffective for Manic Episode of Bipolar Affective Disorder. J Psychopharmacol. 2010;24(1):135-7. PubMed PMID: 18801823.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabidiol was ineffective for manic episode of bipolar affective disorder. AU - Zuardi,Aw, AU - Crippa,Jas, AU - Dursun,Sm, AU - Morais,Sl, AU - Vilela,Jaa, AU - Sanches,Rf, AU - Hallak,Jec, Y1 - 2008/09/18/ PY - 2008/9/20/pubmed PY - 2010/4/16/medline PY - 2008/9/20/entrez SP - 135 EP - 7 JF - Journal of psychopharmacology (Oxford, England) JO - J Psychopharmacol VL - 24 IS - 1 N2 - The pharmacological profile of cannabidiol (CBD) has several characteristics in common with drugs known to benefit bipolar affective disorder (BAD), leading to the hypothesis that CBD may have therapeutic properties in BAD. Therefore, the aim of the present report was to directly investigate for the first time the efficacy and safety of CBD in two patients with BAD. Both patients met DSM IV criteria for bipolar I disorder experiencing a manic episode without comorbid conditions. This was an inpatient study, and the efficacy, tolerability and side effects were assessed. Both patients received placebo for the initial 5 days and CBD from the 6th to 30th day (initial oral dose of 600 mg reaching 1200 mg/ day). From the 6th to the 20th day, the first patient (a 34-year-old woman) received adjunctive olanzapine (oral dose of 10-15 mg). On day 31, CBD treatment was discontinued and replaced by placebo for 5 days. The first patient showed symptoms improvement while on olanzapine plus CBD, but showed no additional improvement during CBD monotherapy. The second patient (a 36-year-old woman) had no symptoms improvement with any dose of CBD during the trial. Both patients tolerated CBD very well and no side-effects were reported. These preliminary data suggest that CBD may not be effective for the manic episode of BAD. SN - 1461-7285 UR - https://www.unboundmedicine.com/medline/citation/18801823/Cannabidiol_was_ineffective_for_manic_episode_of_bipolar_affective_disorder_ L2 - https://journals.sagepub.com/doi/10.1177/0269881108096521?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -